NEUROLEPTIC MALIGNANT SYNDROME

*Sindhu Haris and Kumar S.
PSG Institute of Medical Sciences and Research, Avinashi Rd, Kalluri Nagar, Peelamedu, Coimbatore, Tamil Nadu 641004, India
*Author for Correspondence

ABSTRACT
Neuroleptic Malignant Syndrome is one of the most important causes of the patients on anti-psychotics, present with hyperthermia, rigidity and autonomic dysregulation. It is always prudent to evaluate the patients for NMS, who present with unexplained hyperthermia.

Keywords: Anti-psychotics, Hyperthermia, Rigidity, Autonomic Dysregulation

CASES
A 60 year old man with Bipolar disorder was treated with combination of Fluoxetine 25 mg and Olanzapine 3 mg for 2 years. On his last psychiatric visit, with complaints of excessive episodes of anxiety, Olanzapine dose was increased to 6 mg. After 8 days he presented with high fever of temperature 102.4 F and myalgia, thought of viral etiology and treated with paracetamol. Very next day he was hospitalized with fever of 103 F, fluctuations in Blood Pressure and pulse rate, diaphoresis and rigidity in both upper and lower limbs. Complete blood count, renal function test, CPK, CSF analysis, MRI brain and chest radiography was done. All were unremarkable except elevated white cell count of 15000 cells/mcl, CPK of 2500 U/L (N < 174 U/L) and mild elevation of AST & ALT. Clinical diagnosis of Neuroleptic Malignant syndrome was made. Olanzapine was immediately stopped and supportive treatment was initiated. Fever resolved in 10 hours, rigidity in 24 hours and other manifestations in 8 days.

DISCUSSION
NMS refers to the combination of hyperthermia, hypertonia and autonomic dysregulation occurs as a serious complication of the usage of anti-psychotics. In 1960 French Clinicians first described the term who had been working on a study involving haloperidol. The drugs causing NMS are Haloperidol, chlorpromazine, atypical-anti-psychotic drugs such as Olanzapine, risperidone, ziprasidone, quetiapine. Clozapine with less extra pyramidal effects. Dopaminergic drugs like levodopa, if the dose is reduced abruptly, Metoclopramide, amoxapines, lithium. The mechanism believed to be Dopamine D2 receptor antagonism. D2 receptor blockade in Hypothalamus results in hyperthermia. Hypothalamus, Nigrostriatal pathway and Spinal cord result in extra pyramidal symptoms. Peripheral increased calcium leads to increased contractility. Labile BP, tachycardia, diaphoresis are due to autonomic dysregulation. The incidence is slightly higher in males.

The clinical features are Hyperthermia, hypertonia, diaphoresis, Fluctuations in BP, tachycardia, diaphoresis are due to autonomic dysregulation. The incidence is slightly higher in males.

The treatment of NMS includes discontinuing the offending drug, fluid resuscitation to prevent renal failure due to rhabdomyolysis, anti-pyretic and cooling blankets for hyperthermia. Some patients would need ventilator and circulatory support. Electro convulsive therapy, muscle relaxants like dantrolene sodium, Bromocriptine are useful for rigidity. Differential diagnosis include Lethal catatonia, serotonin syndrome, Malignant hyperthermia and Heat stroke.

Conclusion
Neuroleptic Malignant Syndrome is rare and can be fatal. It should be thought of in patients presenting with unexplained pyrexia, rigidity and autonomous dysfunction. The early diagnosis and treatment are crucial to reduce mortality.

© Copyright 2014 | Centre for Info Bio Technology (CIBTech)
Case Report

REFERENCES